On 12 June, the pharmaceutical companies Eli Lilly and AstraZeneca announced the end of two global Phase 3 trials of the experimental drug lanabecestat, which is an oral beta secretase cleaving enzyme (BACE) inhibitor.

On 19 June, the Portuguese Health Ministry launched the Health Strategy for Dementia.  The Strategy states the principles of care for people with dementia, criteria for prevention, early detection, availability of clinical and comprehensive diagnosis, therapeutic intervention at primary, hospital and specialised care, clarifying the care pathway based on ethical principles, proximity, availability, equity and continuity.

At its meeting of 26 June 2018, the Alzheimer Europe Board condemned the recent decision of the French government to exclude current medicines licensed for the treatment of Alzheimer’s disease from the reimbursement system. Alzheimer Europe and its members organisations fully support the campaign and on-line petition of France Alzheimer which calls for the continued reimbursement of these medicines.

In a report presented today at a lunch debate hosted by MEPs Olga Sehnalová (Czech Republic) and Sirpa Pietikäinen (Finland) in the European Parliament, Alzheimer Europe highlighted significant barriers to timely diagnosis across Europe.